VitriVax is a formulation technology company developing innovative solutions to maximize global accessibility and utility of human and animal vaccines. Our ALTA platform makes vaccines thermostable up to 70°C, and single shot - combining prime and boost doses into one injection.
Location: United States, Colorado, Boulder
Employees: 11-50
Total raised: $5M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Adjuvant C... | adjuvantca... |
| 28.12.2022 | Carolina A... | carolinaan... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.12.2023 | Grant | $5M | - |
Mentions in press and media 4
| Date | Title | Description |
| 22.10.2025 | VitriVax Raises $17.25M in Series B Financing | VitriVax, Inc., a Boulder, CO-based vaccine formulation technology company, raised a total of $17.25m in Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management-. The company intends to use the proceeds from t... |
| 06.12.2023 | Business | Boulder’s VitriVax receives $5M grant from Gates foundation | BOULDER — VitriVax Inc., a Boulder company that is developing vaccine technology, has received a $5 million, two-year grant from the Bill & Melinda Gates Foundation. The grant will help the company to further develop its proprietary sin... |
| 06.12.2023 | VitriVax Receives $5M Grant | VitriVax, a Boulder, CO-based formulation technology company, received $5M two-year grant from Bill & Melinda Gates Foundation. The grant will allow the company to develop further its proprietary single shot, thermostabilization vaccine... |
| 07.07.2021 | VitriVax Raises Series A Financing | VitriVax, a Boulder, Colorado- and Boston, Massachusetts-based developer of a novel stabilization and delivery platform for vaccines and therapeutics, closed its Series A financing round with Adjuvant Capital. The amount of the deal was not... |